flumatinib

an antineoplastic agent and tyrosine kinase inhibitor

Also Known As:

4-(4-methylpiperazin-1-ylmethyl)-N-(6-methyl-5-(4-pyridin-3-ylpyrimidin-2-ylamino)pyridin-3-yl)-3-trifluoromethylbenzamide; HH-GV-678; HH-GV678; HHGV678; flumbatinib

Networked: 14 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chen, Xiaoyan: 2 articles (05/2012 - 08/2010)
2.	Zhong, Dafang: 2 articles (05/2012 - 08/2010)
3.	Chen, L: 1 article (10/2021)
4.	Liu, J: 1 article (10/2021)
5.	Mi, R H: 1 article (10/2021)
6.	Wei, X D: 1 article (10/2021)
7.	Wei, X L: 1 article (10/2021)
8.	Yang, H P: 1 article (10/2021)
9.	Yin, Q S: 1 article (10/2021)
10.	Zhang, L N: 1 article (10/2021)

Related Diseases

1.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/01/2023 - "The present study aimed to investigate the efficacy and safety of flumatinib in patients newly diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). " 08/01/2023 - "To analyze the efficacy and safety of flumatinib in the treatment of patients with chronic myeloid leukemia (CML). " 08/01/2023 - "[Efficacy and Safety of Flumatinib in Treatment of Patients with Chronic Myeloid Leukemia]." 01/01/2023 - "Clinical Efficacy and Safety of Flumatinib in Newly Diagnosed Chronic Myelogenous Leukemia." 01/01/2023 - "Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia."
2.	Philadelphia Chromosome 01/01/2022 - "A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib." 01/01/2021 - "We evaluated the efficacy and safety of flumatinib versus imatinib, for first-line treatment of chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP). " 01/01/2020 - "Flumatinib, indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia, is a structural analog of imatinib and has shown higher potency than imatinib as a BCR-ABL inhibitor. " 01/01/2023 - "Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report."
3.	Multiple Myeloma 12/01/2013 - "The objective of this study was to investigate the effect of the new generation of tyrosine kinase inhibitor flumatinib mesylate on C-MYC, HIF-1α and VEGF in multiple myeloma (MM) cell line U266. "
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/14/2021 - "[Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia]." 02/14/2023 - "[Clinical observation of flumatinib combined with induction chemotherapy and sequential allogeneic hematopoietic stem cell transplantation in the treatment of 6 patients with newly diagnosed Ph(+) acute lymphocytic leukemia]."
5.	Hypophosphatemia 01/01/2021 - "Adverse events of edema, pain in extremities, rash, neutropenia, anemia, and hypophosphatemia were more frequent in imatinib arm, whereas diarrhea and alanine transaminase elevation were more frequent in flumatinib arm. "

Related Drugs and Biologics

1.	Imatinib Mesylate (Gleevec)
2.	Tyrosine Kinase Inhibitors
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	Mesylates (Mesylate)
5.	Antineoplastic Agents (Antineoplastics)
6.	bcr-abl Fusion Proteins
7.	Phosphotransferases (Kinase)
8.	Alanine Transaminase (SGPT)
9.	venetoclax

Related Therapies and Procedures

1.	Induction Chemotherapy
2.	Hematopoietic Stem Cell Transplantation
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)